{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Riluzole+tablet",
    "query": {
      "intervention": "Riluzole tablet"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Riluzole+tablet&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T09:43:52.150Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07142291",
      "title": "PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis (ALS)"
      ],
      "interventions": [
        {
          "name": "Cromolyn Sodium (34.2 mg BID)",
          "type": "DRUG"
        },
        {
          "name": "Cromolyn Sodium (17.1 mg BID)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Riluzole (100 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhenoNet, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 105,
      "start_date": "2025-11-25",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-09-08T09:43:52.150Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07142291"
    },
    {
      "nct_id": "NCT00054704",
      "title": "Riluzole to Treat Depression in Bipolar Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Riluzole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 19,
      "start_date": "2003-02",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2019-04-25",
      "last_synced_at": "2026-09-08T09:43:52.150Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00054704"
    },
    {
      "nct_id": "NCT00419003",
      "title": "Research Study for Major Depressive Disorder: Investigation of Glutamate Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depression"
      ],
      "interventions": [
        {
          "name": "Lamotrigine",
          "type": "DRUG"
        },
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Riluzole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 26,
      "start_date": "2006-12",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2019-07-31",
      "last_synced_at": "2026-09-08T09:43:52.150Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00419003"
    },
    {
      "nct_id": "NCT01709149",
      "title": "Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "CK-2017357",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets",
          "type": "OTHER"
        },
        {
          "name": "Riluzole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Cytokinetics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 711,
      "start_date": "2012-10",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2020-03-31",
      "last_synced_at": "2026-09-08T09:43:52.150Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Orange, California + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01709149"
    },
    {
      "nct_id": "NCT01018056",
      "title": "Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Tourette Syndrome"
      ],
      "interventions": [
        {
          "name": "D-serine",
          "type": "DRUG"
        },
        {
          "name": "Riluzole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 39,
      "start_date": "2009-11",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2018-01-30",
      "last_synced_at": "2026-09-08T09:43:52.150Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01018056"
    },
    {
      "nct_id": "NCT05292209",
      "title": "RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atrial Fibrillation Paroxysmal"
      ],
      "interventions": [
        {
          "name": "Riluzole 50 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2022-06-15",
      "completion_date": "2024-10-30",
      "has_results": false,
      "last_update_posted_date": "2023-11-24",
      "last_synced_at": "2026-09-08T09:43:52.150Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05292209"
    },
    {
      "nct_id": "NCT03017508",
      "title": "Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Social Anxiety Disorder",
        "Performance Anxiety"
      ],
      "interventions": [
        {
          "name": "BHV-0223",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2017-01",
      "completion_date": "2021-01-29",
      "has_results": true,
      "last_update_posted_date": "2021-05-20",
      "last_synced_at": "2026-09-08T09:43:52.150Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03017508"
    },
    {
      "nct_id": "NCT07618715",
      "title": "Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Male and Female Subjects"
      ],
      "interventions": [
        {
          "name": "Y-4 tablet",
          "type": "DRUG"
        },
        {
          "name": "Pregabalin capsule",
          "type": "DRUG"
        },
        {
          "name": "Riluzole tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurodawn Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 11,
      "start_date": "2026-06-30",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-08T09:43:52.150Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07618715"
    },
    {
      "nct_id": "NCT03520517",
      "title": "Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "ALS",
        "Lou Gehrig Disease",
        "Lou Gehrig's Disease",
        "Lou-Gehrigs Disease",
        "Motor Neuron Disease, Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "BHV-0223",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biohaven Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2018-02-02",
      "completion_date": "2018-10-08",
      "has_results": false,
      "last_update_posted_date": "2022-10-06",
      "last_synced_at": "2026-09-08T09:43:52.150Z",
      "location_count": 5,
      "location_summary": "Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Cordova",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03520517"
    },
    {
      "nct_id": "NCT02796755",
      "title": "Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Inflammation",
        "Fatigue"
      ],
      "interventions": [
        {
          "name": "Riluzole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 65 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2016-04",
      "completion_date": "2019-10-24",
      "has_results": true,
      "last_update_posted_date": "2021-04-14",
      "last_synced_at": "2026-09-08T09:43:52.150Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02796755"
    }
  ]
}